I think we are severely undervalued due to lack of 'exciting' news.
Customer contract value has been increasing QoQ, just under 2m cash on hand = approx 1 year of operating with current eb and flow. We can only expect to see increased sales, esp with the new NBIOT devices.
2017 Q4 - $500,000
2017 Q3 - $440,000
2017 Q2 - $340,000
2017 Q1 - $275,000
The market will wake up, just a matter of time.
I think we are severely undervalued due to lack of 'exciting'...
Add CT1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.474M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 22494991 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 5996627 | 5 |
View Market Depth
| Last trade - 16.12pm 29/11/2024 (20 minute delay) ? |
| CT1 (ASX) Chart |
Day chart unavailable
